Seres Therapeutics Inc logo

Seres Therapeutics Inc

$ 6.54 +0.01 (+0.15%) 10:08 PM EST
P/E:
At Loss
P/B:
12.11
Market Cap:
$ 814.83M
Enterprise V:
$ 656.62M
Volume:
555.70K
Avg Vol (2M):
830.37K
Also Trade In:
Volume:
555.70K
Market Cap $:
814.83M
PE Ratio:
At Loss
Avg Vol (2-Month):
830.37K
Enterprise Value $:
656.62M
PB Ratio:
12.11

Business Description

Description
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Name Current Vs Industry Vs History
Cash-To-Debt 3.06
Equity-to-Asset 0.22
Debt-to-Equity 1.13
Debt-to-EBITDA -0.35
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.29
Distress
Grey
Safe
Beneish M-Score -5.78
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 49
9-Day RSI 46.04
14-Day RSI 46.42
6-1 Month Momentum % 91.4
12-1 Month Momentum % -27.72

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.03
Quick Ratio 3.03
Cash Ratio 2.85
Days Sales Outstanding 31.6

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -30.9